P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION

Eitemau Tebyg

• P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
  gan: Madlen Jentzsch, et al.
  Cyhoeddwyd: (2023-08-01)
• Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
  gan: Madlen Jentzsch, et al.
  Cyhoeddwyd: (2022-12-01)
• P508: THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS
  gan: Lara Bischof, et al.
  Cyhoeddwyd: (2023-08-01)
• PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
  gan: Jule Ussmann, et al.
  Cyhoeddwyd: (2023-08-01)
• Sex-associated differences in outcome of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation
  gan: Jule Ussmann, et al.
  Cyhoeddwyd: (2025-06-01)